NEW YORK (360Dx) – Arquer Diagnostics announced today that it has been awarded a  £70,000 ($86,038) grant from Innovate UK to prepare for a clinical study of its ELISA-based noninvasive prostate cancer test.

The test — called MCM5-ELISA — detects minichromosome maintenance, a protein biomarker of dividing cancer cells. The planned study will evaluate the test using urine and semen samples from up to 100 patients and help the company design a larger clinical trial that is expected to start later this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.